Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus paracasei PC-01
- Development stage
- Unknown
- Lead developer
- Mengniu
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus paracasei PC-01 is a specific probiotic strain belonging to the Lacticaseibacillus paracasei species, primarily investigated for its therapeutic potential in gastrointestinal disorders. Developed and studied by researchers at the West China School of Public Health, Sichuan University, in collaboration with By-Health Co., Ltd., it is being evaluated as a live biotherapeutic product for the treatment of functional dyspepsia (FD). The strain is thought to exert its effects by modulating the gut microbiota composition, enhancing intestinal barrier integrity, and potentially influencing the gut-brain axis to improve gastric motility and reduce visceral hypersensitivity. Clinical evidence from randomized, double-blind, placebo-controlled trials suggests that oral administration of PC-01 can significantly alleviate symptoms of functional dyspepsia, including postprandial fullness and epigastric pain, thereby improving the quality of life for affected patients.
- Other names
- L. paracasei PC-01Lacticaseibacillus paracasei PC-01
Beyond the preview
Go deeper on Lactobacillus paracasei PC-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus paracasei PC-01.